Potentiation of Chemotherapy in Brain Tumors by Zinc
关键词
抽象
描述
We propose a single arm phase II clinical trial in 30 newly diagnosed GBM patients who will be treated with the standard chemo-radiotherapy with the addition of daily zinc. We will follow the toxicity, Progression free survival and overall survival of this group of patients. We hope to demonstrate the anti-tumor activity of zinc that will enhance the activity of temozolomide chemotherapy in adult glioblastoma patients. We will also follow the safety and monitor quality of life during treatment. In this study, we will compare results of patients receiving zinc to historical patient data. We will review patient portfolios with GB tumors that received treatment as the subjects in this study in the last five years before the study began. Collecting the data and separating the identified data from the file in a way that cannot be retrieved in any way will be done by a staff member from Dr Ruty Shai's laboratory who is authorized to open medical files. We will adjust the age and number of patients in each gender. Data collected: date of birth, age of disease development, gender, data after receiving treatment: Progression free survival and overall survival of this group of patients, side effects, and quality of life.
日期
最后验证: | 06/30/2020 |
首次提交: | 07/21/2020 |
提交的预估入学人数: | 07/26/2020 |
首次发布: | 07/27/2020 |
上次提交的更新: | 07/26/2020 |
最近更新发布: | 07/27/2020 |
实际学习开始日期: | 07/29/2020 |
预计主要完成日期: | 07/29/2022 |
预计完成日期: | 12/29/2022 |
状况或疾病
干预/治疗
Dietary Supplement: Glioblastoma patients
相
手臂组
臂 | 干预/治疗 |
---|---|
Experimental: Glioblastoma patients newly diagnosed GB who underwent at least partial resection of the tumor surgically | Dietary Supplement: Glioblastoma patients oral zinc and ascorbate |
资格标准
有资格学习的年龄 | 18 Years 至 18 Years |
有资格学习的性别 | All |
接受健康志愿者 | 是 |
标准 | Inclusion Criteria: - Males and Females, - age ≥ 18 years old, - newly diagnosed GBM, Karnofsky performance status of ≥ 70, - after partial resection or gross tumor resection (GTR) who recovered from surgical resection. Exclusion Criteria: - GB patients with less than 20% of tumor removed, - Prior treatment for GB (other than surgical resection), - any known malignancy outside of the brain in the last 5 years, - in ability to swallow drugs. |
结果
主要结果指标
1. progression free survival (PFS) [year 1]
2. overall survival (OS) [year 2]
次要成果指标
1. Tcell count [year 2]
2. Level of Interleukin 6 [year 2]
3. Tumor Necrosis Factor quantification [year 2]